- Home
- BDTX vs MIRM Comparison
BDTX vs MIRM Comparison
Compare BDTX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | MIRM |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.3M | 3.7B |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BDTX | MIRM |
|---|---|---|
| Price | $2.80 | $65.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $10.60 | ★ $87.55 |
| AVG Volume (30 Days) | ★ 1.8M | 545.4K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | $70,000,000.00 | ★ $471,794,000.00 |
| Revenue This Year | N/A | $53.78 |
| Revenue Next Year | N/A | $19.91 |
| P/E Ratio | $7.38 | ★ N/A |
| Revenue Growth | N/A | ★ 53.66 |
| 52 Week Low | $1.20 | $36.88 |
| 52 Week High | $4.94 | $78.55 |
Technical Indicators
Market Signals| Indicator | BDTX | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 36.47 |
| Support Level | $2.61 | $63.66 |
| Resistance Level | $2.87 | $66.77 |
| Average True Range (ATR) | 0.26 | 2.99 |
| MACD | -0.08 | -0.66 |
| Stochastic Oscillator | 33.82 | 13.68 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.